New-CeraShield

Next standard of care in Hospital Acquired Infection (HAI) prevention

CeraShield™

Biofilm-resistant endotracheal tube

Designed to reduce ventilator associated respiratory infections (VARI) and significantly lower overall cost of care

The CeraShield™ ETT is approved for marketing in Canada and Belize with other approvals pending.
The CeraShield™ ETT is an investigational device in the United States.

Next standard of care in Hospital Acquired Infection (HAI) prevention

CeraShield™

Biofilm-resistant endotracheal tube

Designed to reduce ventilator associated respiratory infections (VARI)
and significantly lower overall cost of care

The CeraShield™ ETT is approved for marketing in Canada and Belize with other approvals pending. The CeraShield™ ETT is an investigational device in the United States.

Download Brochure
Interested in Evaluating?

CeraShield™ ETT

Medical device-associated biofilms pose a serious threat to human health and lead to nosocomial infections

New strategies are urgently needed

Up to 80% of microbial infections in the human body involve biofilm formation, especially in hospital settings, which greatly promotes the incidence rate and mortality 1,2

Over 6 million potential deaths from nosocomial infections worldwide each year 3

50–70% of nosocomial infections are related to indwelling medical devices.

Ordinary medical devices allow millions of pathogenic CFUs to grow within hours and act as a reservoir of infectious agents, leading to inflammation and infection.
The resistance of bacteria in biofilms to antibiotics can be 10–1,000X that of the corresponding planktonic cells. 5
The rates of horizontal plasmid transfer were several orders of magnitude higher in the biofilms than in liquid cultures of the same organisms. 6
1. Jamal, m.; ahmad, w.; andleeb, s.; jalil, f.; imran, m.; nawaz, m.a.; hussain, t.; ali, m.; rafiq, m.; kamil, m.a. bacterial biofilm and associated infections. j. chin. med. assoc. 2018, 81, 7–11.
2. Khatoon, z.; mctiernan, c.d.; suuronen, e.j.; mah, t.-f.; alarcon, e.i. bacterial biofilm formation on implantable devices and approaches to its treatment and prevention. heliyon 2018, 4, e01067..
3. Gyawali b, ramakrishna k, dhamoon as. sepsis: the evolution in definition, pathophysiology, and management. sage open med. 2019;7:2050312119835043. published 2019 mar 21. doi:10.1177/2050312119835043..
4. Yasir, m.; willcox, m.d.p.; dutta, d. action of antimicrobial peptides against bacterial biofilms. materials 2018, 11, 2468..
5. Kisil, o.v.; efimenko, t.a.; gabrielyan, n.i.; efremenkova, o.v. development of antimicrobial therapy methods to overcome the antibiotic resistance of acinetobacter baumannii. acta nat. 2020, 12, 34–45..
6. Rodney m. donlan, biofilm formation: a clinically relevant microbiological process, clinical infectious diseases, volume 33, issue 8, 15 october 2001, pages 1387–1392, https://doi.org/10.1086/322972.

CeraShield™ biofilm-resistant coating works to prevent infection and inflammation

Ordinary ETT
CeraShieldTM Biofilm-Resistant ETT
CeraShield™ coating mimics the activity of the human body’s innate immune system, which does not induce antimicrobial resistance (AMR)

Creates hydration layer that inhibits bacterial adhesion to the surface, creating a “moat” around the device.

The CeraShield™ coating’s net positive charge attracts the negatively-charged membranes of certain viruses, fungi, and bacteria.

As the CeraShield™ coating and pathogen get closer together, the CeraShield™ coating begins to permeabilize and depolarize the cell
membrane, leading to rapid cell death.

VENTILATOR-ASSOCIATED PNEUMONIA: WHAT IS THE REAL COST?

Each added case of ventilator
respiratory infection adds between
$10,000–$50,000 (US). 7

The total preventable cost worldwide is >$10 billion. 8
9-13%
attributable risk of death 9
Approximately 50% of all critical care antibiotics are for treatment for VAP 9,11

INTRODUCING THE PROPRIETARY CERASHIELD™ COATED BACTERIA-RESISTANT ENDOTRACHEAL TUBE

By preventing biofilm, we can significantly prevent VAP and other adverse outcomes

Designated as “breakthrough device” by FDA

Indication

The CeraShield™ endotracheal tube is to be used for airway management in adult patients expected to be intubated ≥ 24 hours.
The CeraShield™ ETT consists of:
  • A standard adult cuffed ETT manufactured and sourced from Flexicare offered in sizes 7.0mm–8.5mm
  • A hydrophilic anti-fouling coating on the inner and outer lumens, and the inflatable cuff

Contact us

Lets Get in Touch!

  • info@n8medical.com
  • N8 Medical, LLC1090 Center DrivePark City, UT 84098
Follow now
Linkedin

mynewform

Basic contact form

N8 Medical, Inc. (N8 Medical) is a clinical-stage medical device company focused on commercializing medical devices that incorporate a novel class of active compounds called ceragenins.The subsidiaries for N8 Medical Inc are N8 Medical, LLC for Medical Device Development and Kinnear Pharmaceuticals, LLC for drug development.

Useful Links

Our Company